Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference
August 04 2021 - 7:00AM
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company focused on discovering and developing
small molecule therapeutics targeting fundamental biological
pathways of cancers, today announced that Anthony Sun, MD, Chairman
and Chief Executive Officer of Zentalis, will participate in a
panel discussion at the Wedbush PacGrow Healthcare Virtual
Conference on Wednesday, August 11, 2021 at 10:20 a.m. ET.
A live webcast will be accessible though the
Investors section of the Company’s website at www.zentalis.com.
About Zentalis
Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on discovering and
developing small molecule therapeutics targeting fundamental
biological pathways of cancers. The Company is developing a broad
pipeline of potentially best-in-class oncology candidates, all
internally discovered, which include ZN-c3, a WEE1 inhibitor for
advanced solid tumors, ZN-c5, an oral selective estrogen receptor
degrader (SERD) for ER+/HER2- breast cancer, ZN-d5, a BCL-2
inhibitor for hematologic malignancies, and ZN-e4, an EGFR
inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has
licensed ZN-c3, ZN-c5 and ZN-d5 to its majority-owned joint
venture, Zentera Therapeutics, to develop and commercialize these
candidates in China. Zentalis has operations in both New York and
San Diego.
For more information, please
visit www.zentalis.com. Follow Zentalis on Twitter
at @ZentalisP and on LinkedIn
at www.linkedin.com/company/zentalis-pharmaceuticals.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding our participation in upcoming events and
presentations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to the
important factors discussed under the caption “Risk Factors” in our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2021
filed with the U.S. Securities and Exchange Commission (SEC) and
our other filings with the SEC. Any such forward-looking statements
represent management’s estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to
change.Investor Contact:Gitanjali Jain
OgawaSolebury Troutgogawa@soleburytrout.com
Media Contact:Julia
DeutschSolebury Troutjdeutsch@soleburytrout.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Apr 2023 to Apr 2024